https://clinicaltrials.gov/ct2/show/NCT04018599?type=Intr&cond=ankylosing+spondylitis&phase=0124&lupd_s=09%2F06%2F2019&lupd_d=14&sort=nwst
STUDY TITLE:
Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
DESCRIPTION:
Conditions: Rheumatoid Arthritis; Polyarticular Juvenile Idiopathic Arthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Crohn Disease; Ulcerative Colitis; Plaque Psoriasis; Pediatric Plaque Psoriasis; Pediatric Crohns Disease; Hidradenitis Suppurativa; Non-infectious Uveitis
Intervention: Drug: 40 mg MSB11022
Sponsors: Fresenius Kabi SwissBioSim GmbH; PRA Health Sciences
Recruiting
CLINICALTRIALS.GOV IDENTIFIER:
NCT04018599
FIRST POSTED:
Fri, 12 Jul 2019 12:00:00 EDT
LAST UPDATE POSTED:
09/20/19 07:01AM
STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04018599?type=Intr&cond=ankylosing+spondylitis&phase=0124&lupd_s=09%2F06%2F2019&lupd_d=14&sort=nwst
